Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome | Zendy

Ilse C. Schrieks | Zendy; Anozza | Zendy; Barbara E. Stähli | Zendy; John B. Buse | Zendy; Robert R. Henry | Zendy; Klas Malmberg | Zendy; Bruce Neal | Zendy; Stephen J. Nicholls | Zendy; Lars Rydén | Zendy; Linda Mellbin | Zendy; Anders Svensson | Zendy; Hans Wedel | Zendy; Arlette Weichert | Zendy; A. Michael Lincoff | Zendy; JeanClaude Tardif | Zendy; Diederick E. Grobbee | Zendy; Gregory G. Schwartz | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome

Author(s) -

Ilse C. Schrieks,

Anozza,

Barbara E. Stähli,

John B. Buse,

Robert R. Henry,

Klas Malmberg,

Bruce Neal,

Stephen J. Nicholls,

Lars Rydén,

Linda Mellbin,

Anders Svensson,

Hans Wedel,

Arlette Weichert,

A. Michael Lincoff,

JeanClaude Tardif,

Diederick E. Grobbee,

Gregory G. Schwartz

Publication year - 2018

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc18-0158

Subject(s) - adiponectin , medicine , hazard ratio , myocardial infarction , acute coronary syndrome , diabetes mellitus , type 2 diabetes , proportional hazards model , cardiology , metabolic syndrome , endocrinology , insulin resistance , obesity , confidence interval

In observational cohorts, adiponectin is inversely associated and free fatty acids (FFAs) are directly associated with incident coronary heart disease (CHD). Adiponectin tends to be reduced and FFAs elevated in type 2 diabetes. We investigated relationships of adiponectin and FFA and major adverse cardiovascular events (MACEs) and death in patients with acute coronary syndrome (ACS) and type 2 diabetes using data from the AleCardio (Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus) trial, which compared the PPAR-α/γ agonist aleglitazar with placebo.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research